NasdaqHealth CareHealth Care EquipmentS&P MidCap 400
$61.31
+3.25 (+5.60%)
Close of Nov 06, 2026 · end-of-day data
BRKR 8-K filings in 2026
Every material Form 8-K Bruker filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Effective July 1, 2026, Bruker reorganized its reportable segments, with BSI BIOS, BSI BMID, BSI NANO and BEST now reported. The company furnished recast segment data for 2024, 2025 and 2026 periods so investors can compare on the new basis. The filing states the change has no effect on historical consolidated results of operations, financial position or cash flows, and is not a restatement.
Reorganization effective July 1, 2026 creates four reportable segments: BSI BIOS, BSI BMID, BSI NANO and BEST.
Exhibit 99.1 provides recast segment data for fiscal 2025 and 2024, quarterly 2025 and 2026 periods, and the nine months ended September 30, 2025.
Fiscal 2025 revenue from external customers is $3.4 billion on both the as-reported and recast bases, per the exhibit.
Bruker reported third-quarter 2026 revenue of $874.0 million, up 1.6% from a year earlier, and non-GAAP diluted EPS of $0.56, up 24.4%. GAAP results were a diluted loss of $(0.81) per share, driven by a $174.5 million goodwill impairment charge, and the company reconfirmed its FY26 organic revenue growth and non-GAAP EPS guidance of $2.10 to $2.15.
Q3-26 revenue $874.0 million, up 1.6% yoy; organic growth 0.7%
Q3-26 non-GAAP diluted EPS $0.56, up 24.4% from $0.45; GAAP diluted loss $(0.81) vs. $(0.41) a year earlier
Q3-26 GAAP operating loss $(91.0) million, including a $174.5 million goodwill impairment charge
FY26 non-GAAP EPS outlook of $2.10 to $2.15 reconfirmed; FY26 revenue guidance $3.52 to $3.56 billion
Bruker Corporation's board declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend is payable December 1, 2026, to holders of record at the close of business on November 15, 2026. This is a routine dividend declaration that sets the payment and record dates for preferred shareholders.
Dividend of $3.9844 per share declared October 29, 2026
Payable December 1, 2026
Record date is the close of business on November 15, 2026
Bruker reported second-quarter 2026 revenue of $838.5 million, up 5.2% year over year, and non-GAAP diluted EPS of $0.49, up from $0.32. A $134.9 million goodwill impairment produced a GAAP diluted loss of $(0.41) per share, and FY26 non-GAAP EPS guidance of $2.10 to $2.15 was kept, with the outlook updated only for currency and tax.
Q2 revenue of $838.5 million, up 5.2%; organic growth was 2.8%, or 3.4% excluding tariff refunds
GAAP diluted loss of $(0.41) per share versus $0.05 a year earlier, including a $134.9 million goodwill impairment charge
Non-GAAP diluted EPS of $0.49 versus $0.32; non-GAAP operating margin of 14.1% versus 9.0%
FY26 non-GAAP EPS guidance of $2.10 to $2.15 unchanged; currency tailwind to revenue cut to approximately 0.5% from 1.5%
Bruker reported first quarter 2026 revenue of $823.4 million, up 2.7% from a year earlier, but organic revenue fell 4.4%. Non-GAAP diluted EPS was $0.31 versus $0.47 a year earlier, and GAAP diluted EPS was $0.02 versus $0.11, so profit declined even as sales rose. The company reconfirmed its prior fiscal 2026 guidance for revenue of $3.57 to $3.60 billion and non-GAAP EPS of $2.10 to $2.15.
Q1 2026 revenue $823.4 million, up 2.7% year over year; organic revenue down 4.4%
Non-GAAP diluted EPS $0.31 vs. $0.47 in Q1 2025; GAAP diluted EPS $0.02 vs. $0.11
Non-GAAP operating margin 10.2% vs. 12.7% a year earlier
FY2026 guidance reconfirmed: revenue $3.57 to $3.60 billion and non-GAAP EPS $2.10 to $2.15
Bruker Corporation said executive officer Falko Busse, President of Bruker BioSpin, will transition out of his duties on or around May 1, 2026, with his employment ending October 31, 2026. His separation agreement provides severance, a pro-rated bonus and unused vacation payout totaling approximately $1,020,351, and he will forfeit unvested equity awards.
Duties transition on or around May 1, 2026; employment ends October 31, 2026
Separation benefits total approximately $1,020,351, payable on the separation date
Unvested equity awards held by Dr. Busse will be forfeited
Full separation agreement will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2026
Bruker Corporation expanded its board to twelve directors and appointed Thierry L. Bernard, who is CEO and Managing Director of QIAGEN N.V., as a director effective April 1, 2026. Bernard will serve until the 2027 Annual Meeting of Stockholders, and QIAGEN has announced he will step down as CEO once a successor is appointed.
Board increased from eleven to twelve directors; Bernard assigned to Class III and serves until the 2027 Annual Meeting
Bernard is CEO and Managing Director of QIAGEN N.V. (NYSE: QGEN); QIAGEN announced his CEO transition in November 2025
Bruker will file an amended Form 8-K to disclose Bernard's committee assignments once determined
Bruker Corporation disclosed that director Cynthia M. Friend will not stand for re-election at the 2026 Annual Meeting, though she will serve out her term, and that its board declared a quarterly cash dividend of $0.05 per share payable April 7, 2026. The filing also says Jack Phillips was re-elected as a Class II director after stepping down from Class III, with his board service treated as uninterrupted since January 1, 2026.
Dr. Cynthia M. Friend, a director since May 2016 and member of the Compensation Committee, will not stand for re-election when her Class II term expires; the filing says the decision involves no disagreement with the company.
Quarterly cash dividend of $0.05 per share declared February 19, 2026, payable April 7, 2026, to holders of record at the close of business on March 23, 2026.
Jack Phillips stepped down as a Class III director on February 19, 2026, and was immediately re-elected as a Class II director; he will stand for re-election at the 2026 Annual Meeting.
Bruker reported fourth-quarter 2025 revenue of $977.2 million, flat year over year, and non-GAAP diluted EPS of $0.59 versus $0.76 a year earlier. For the full year, revenue rose 2.1% to $3.44 billion, but the company posted a GAAP diluted loss of $(0.15) per share after $127.2 million of goodwill and intangible impairment charges and $77.4 million of restructuring charges. For 2026, Bruker guided to revenue of $3.57 to $3.60 billion and non-GAAP EPS of $2.10 to $2.15.
Q4-25 revenue of $977.2 million, down 0.2% year over year; non-GAAP diluted EPS of $0.59 versus $0.76 in Q4-24
FY25 GAAP diluted loss per share of $(0.15) versus EPS of $0.76 in FY24, reflecting $127.2 million in impairment charges and $77.4 million in restructuring charges
FY26 guidance: revenue of $3.57 to $3.60 billion and non-GAAP EPS of $2.10 to $2.15, including a currency headwind of about $0.15 per share
Management said the Q4 margin recovery lagged prior guidance, so cost-savings initiatives were expanded beyond the previous range
On January 12, 2026, Bruker said during a J.P. Morgan Healthcare Conference presentation that preliminary fourth-quarter 2025 revenue is expected to be between $965 million and $970 million. It also outlined a preliminary 2026 outlook calling for flat to low-single-digit organic revenue growth, organic operating margin expansion of 250 to 300 basis points, and double-digit non-GAAP earnings per share growth, each compared with 2025. The fourth-quarter and full-year figures are unaudited and not yet finalized, and final results may differ materially.
Preliminary Q4 2025 revenue expected between $965 million and $970 million
Fourth-quarter 2025 Bruker Scientific Instruments book-to-bill ratio above 1.0
2026 outlook: organic revenue growth flat to up low-single digits versus 2025
2026 outlook: non-GAAP organic operating margin to expand 250 to 300 basis points and non-GAAP EPS to grow in double digits
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bruker filing is on SEC EDGAR ↗. 8-K briefs of other companies →